Plasminogen Therapy for Cardiac Lesion Mitigation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiac lesions, particularly those caused by myocardial injury and cardiac dysfunction, are inadequate in addressing the underlying pathologies of atherosclerosis and lipid metabolism disorders, which contribute to increased morbidity and mortality in diabetic patients.
Innovation Solution
Administering plasminogen to prevent or treat myocardial injury by alleviating apoptosis, promoting repair, and reducing fibrosis in cardiac tissue, thereby improving myocardial function and addressing lipid-induced injuries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cardiac lesions are used, then conventional therapy is provided, but they are inadequate in addressing underlying pathologies of atherosclerosis and lipid metabolism disorders
Solution Approach 1:
The patent uses plasminogen as an intermediary substance to bridge the gap between conventional therapy and the underlying pathologies. Plasminogen activates plasmin, which then addresses multiple underlying issues including atherosclerosis, lipid metabolism disorders, and myocardial injury simultaneously, making the treatment more versatile and effective.
Solution Approach 2:
The patent applies plasminogen which has multiple functions: it addresses atherosclerosis, lipid metabolism disorders, myocardial injury, and cardiac dysfunction. This single substance performs multiple therapeutic roles, making the treatment adaptable to various underlying pathologies rather than requiring separate treatments for each condition.
2Reliability
If plasminogen is administered to treat myocardial injury, then cardiac tissue repair is promoted, but the mechanism involves multiple pathways including apoptosis inhibition and fibrosis reduction
Solution Approach 1:
The patent segments the complex treatment mechanism into distinct actionable pathways: inhibition of apoptosis, promotion of repair, and reduction of fibrosis. By breaking down the overall therapeutic effect into these separate mechanisms, the patent provides a clearer understanding of how plasminogen works while maintaining comprehensive treatment effectiveness.
3Object-affected harmful factors
If plasminogen reduces lipid deposition in cardiac tissue, then lipid-induced injuries are mitigated, but this requires addressing the root cause of lipid metabolism disorders
Solution Approach 1:
The patent converts the harmful accumulation of lipids in cardiac tissue into a beneficial therapeutic target. By using plasminogen to reduce lipid deposition, the treatment transforms the existing lipid burden into an addressable issue, mitigating lipid-induced injuries while improving overall cardiac health and metabolism.
Data Source
AI summary
The present invention relates to a method for preventing and/or treating hyperlipemia and its related conditions in a subject, comprising administering a prophylactically and/or therapeutically effective amount of plasminogen to the subject susceptible to hyperlipemia, suffers from hyperlipemia or other diseases accompanied by hyperlipemia. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating hyperlipemia and its related conditions in a subject.